Comparison · NCT04684524-sae
Dupilumab vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dupilumab vs Placebo: serious adverse events. Trial comparisons, record NCT04684524-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04684524-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.104 | wilson | |
| Risk in group 2 | 0.107 | 0.0371 | 0.272 | wilson | |
| Risk difference, group 1 minus group 2 | -0.107 | -0.272 | 0.0185 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with a serious adverse event on Dupilumab than on Placebo | 9.33 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dupilumab | Participants received dupilumab depending on the weight at screening via SC injection for 52 weeks as follows:~* 300 mg q2w for all adults and adolescents/children weighing \>=60 kg~* 200 mg q2w for adolescents/children weighing \>=30 kg and \<60 kg~* 300 mg q4w for adolescents/children weighing \>=15 kg and \<30 kg. | 0 | 33 | EG001 |
| Group 2 | Placebo | Participants received placebo matched to dupilumab via SC injection for 52 weeks. | 3 | 28 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events and deaths were assessed from first dose of study drug (Day 1) up to end of follow-up per participant, up to approximately 64 weeks
Source ClinicalTrials.gov
Trial
- Title
- Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)
- NCT number
- NCT04684524
- Phases
- PHASE3
- Conditions
- Allergic Fungal Rhinosinusitis
- Interventions
- Dupilumab SAR231893, Placebo
- Lead sponsor
- Sanofi
- Results first posted
- 2025-12-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04684524?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04684524-sae